SequelSEC

Nuo Therapeutics, Inc. AURX

Surgical & Medical Instruments & Apparatus · CIK 0001091596 · Fiscal year ends 1231

Revenue
$3.31M
Fiscal year ended 2025-12-31
Operating income
-$2.52M
Fiscal year ended 2025-12-31
Free cash flow
-$1.14M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$41.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.85Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue12.4×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth142.7%95th
Current ratio1.06x15th
CapEx / revenue8.3%79th
Operating margin-76.0%28th
Net margin-75.8%29th
SBC / revenue2.6%30th
Gross margin66.9%62th
FCF margin-34.4%38th

Nuo Therapeutics, Inc. (AURX) reported revenue of $3.31M and net income of -$2.51M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Nuo Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

Nuo Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312015-12-31
Revenue$3.31M$1.37M$608.52K$112.25K$0$0$146.18K$1.37M$721.04K$11.51M
Cost of revenue$1.10M$302.84K$126.09K$19.21K$0$0$114.61K$162.99K$1.09M$7.97M
Gross profit$2.22M$1.06M$482.43K$93.04K$0$0$31.56K$1.21M-$370.00K$3.54M
Operating income-$2.52M-$2.46M-$3.17M-$3.32M-$90.67K-$378.06K-$969.20K-$1.50M-$15.53M-$41.32M
Net income-$2.51M-$2.32M-$3.17M-$3.17M-$90.67K-$90.87K-$1.19M-$1.54M-$14.98M-$52.81M
Research & developmentUnavailableUnavailableUnavailableUnavailable$0$0$181.18K$576.19K$1.33M$2.55M
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableshares 30.30Mshares 27.31Mshares 23.72Mshares 23.28Mshares 14.65MUnavailable
Pretax income-$2.51M-$2.32M-$3.17M-$3.17M-$90.67K-$90.87K-$1.19M-$1.54M-$14.98M-$52.90M
Income tax expense$0$0$0$0$0$0$0UnavailableUnavailable-$89.01K
Diluted EPSUnavailableUnavailableUnavailableUnavailable$-0.03$0.27$-0.05$-0.07$-1.02Unavailable
Selling, general & administrative$4.73M$3.52M$3.65M$3.41M$90.67K$378.06K$819.58K$2.14M$4.54M$15.26M
General & administrativeUnavailableUnavailableUnavailableUnavailable$90.67K$378.06K$789.12K$2.02M$3.82M$9.02M
Selling & marketingUnavailableUnavailableUnavailableUnavailable$0$0$30.46K$114.88K$712.74K$6.24M

Balance

Nuo Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312015-12-31
Cash & equivalents$548.95K$283.71K$928.68K$2.05M$1.41M$161.43K$20.25K$636.93K$693.52K$922.32K
Total assets$1.85M$1.19M$1.88M$3.05M$1.47M$161.43K$276.55K$975.50K$1.42M$7.07M
Current assets$1.38M$841.55K$1.56M$2.63M$1.47M$161.43K$276.55K$866.69K$1.19M$3.05M
Total liabilities$2.80M$675.80K$838.73K$856.02K$673.08K$664.95K$1.49M$1.06M$941.17K$43.13M
Current liabilities$1.31M$578.45K$674.53K$600.43K$673.08K$664.95K$1.49M$1.06M$936.84K$42.19M
Total equity incl. NCI-$956.56K$513.71K$1.04M$2.19M$792.84K-$503.52K-$1.21M-$81.99K$482.87K-$36.56M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$500.00K
Inventory$213.76K$150.44K$209.59K$240.00K$0UnavailableUnavailable$25.35K$35.59K$254.38K
Accounts receivable$561.67K$248.20K$250.70K$92.32K$0$0$0UnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0
Long-term debtUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$436.08K$219.19K$394.52K$397.70K$526.56K$518.43K$538.67K$437.32K$380.28K$1.07M

Cash flow

Nuo Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312015-12-31
Operating cash flow-$864.97K-$2.23M-$3.17M-$3.71M-$119.96K-$53.82K-$921.67K-$874.39K-$4.90MUnavailable
Capital expenditures$274.76K$154.96K$7.24K$59.99K$0$0$0UnavailableUnavailable$698.17K
Investing cash flow-$274.76K-$154.96K-$7.24K-$59.99K$0$0$0$2.00K$1.91KUnavailable
Financing cash flow$1.40M$1.74M$2.00M$4.46M$1.37M$195.00K$305.00K$815.80K$2.92MUnavailable
Net change in cash$265.23K-$644.97K-$1.18M$691.64K$1.25M$141.18K-$616.67K-$56.59K-$1.98M-$15.02M
Stock-based compensation$85.99K$56.65K$21.75K$9.14K$13.94K$333.63K$50.00K$7.10K$53.53K$782.76K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$471Unavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable$0$0$89.86K$102.20K$1.11M$433.00K

Derived

Nuo Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312015-12-31
Free cash flow-$1.14M-$2.39M-$3.18M-$3.77M-$119.96K-$53.82K-$921.67KUnavailableUnavailableUnavailable
Gross margin66.9%77.8%79.3%82.9%UnavailableUnavailable21.6%88.1%-51.3%30.8%
Operating margin-76.0%-180.0%-520.6%-2958.2%UnavailableUnavailable-663.0%-109.8%-2154.4%-359.0%
FCF margin-34.4%-174.8%-521.8%-3355.1%UnavailableUnavailable-630.5%UnavailableUnavailableUnavailable
SBC / revenue2.6%4.1%3.6%8.1%UnavailableUnavailable34.2%0.5%7.4%6.8%
Current ratio1.06x1.45x2.32x4.39x2.18x0.24x0.19xUnavailable1.27x0.07x
Revenue YoY growth142.7%124.3%442.1%UnavailableUnavailable-100.0%-89.3%90.1%UnavailableUnavailable
Net margin-75.8%-170.2%-521.2%-2825.6%UnavailableUnavailable-817.4%-112.5%-2077.4%-458.8%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable123.9%42.0%184.2%22.2%
CapEx / revenue8.3%11.4%1.2%53.4%UnavailableUnavailable0.0%UnavailableUnavailable6.1%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AURX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.